An essential domain of the c-myc protein interacts with a nuclear factor that is also required for E1A-mediated transformation

Cell transformation by nuclear oncogenes such as c-myc presumably involves the transcriptional activation of a set of target genes that participate in the control of cell division. The function of a small evolutionarily conserved domain of the c-myc gene encompassing amino acids 129 to 145 was analyzed to explore the relationship between cell transformation and transcriptional activation. Deletion of this domain inactivated the c-myc oncogene for cell transformation while retaining the ability to activate transcription of either myc consensus binding sites or a GAL4-dependent promoter when the c-myc N-terminus was fused to the GAL4 DNA-binding domain. Point mutations that altered a conserved tryptophan (amino acid 136) within this domain had similar effects. Expression of the wt c-Myc N terminus (amino acids 1 to 262) as a GAL4 fusion was a dominant inhibitor of cell transformation by the c-myc oncogene, and this same domain also inhibited transformation by the adenovirus E1A gene. Surprisingly, deletion of amino acids 129 to 145 eliminated the dominant negative activity of GAL4-Myc on both c-myc and E1A transformation. Expression of the GAL4-Myc protein in Cos cells led to the formation of a specific complex between the Myc N terminus and a nuclear factor, and this complex was absent with the dl129-145 mutant. These results suggest that an essential domain of the c-Myc protein interacts with a specific nuclear factor that is also required for E1A transformation.

[1]  C. Sawyers,et al.  Dominant negative MYC blocks transformation by ABL oncogenes , 1992, Cell.

[2]  J. Flint,et al.  Transcriptional and transforming activities of the adenovirus E1A proteins. , 1991, Advances in cancer research.

[3]  A. Rustgi,et al.  Amino-terminal domains of c-myc and N-myc proteins mediate binding to the retinoblastoma gene product , 1991, Nature.

[4]  L. Su,et al.  TFE3: a helix-loop-helix protein that activates transcription through the immunoglobulin enhancer muE3 motif. , 1990, Genes & development.

[5]  R. Kingston,et al.  DNA binding activities of c-Myc purified from eukaryotic cells. , 1992, The Journal of biological chemistry.

[6]  R. Roeder,et al.  The adenovirus major late transcription factor USF is a member of the helix-loop-helix group of regulatory proteins and binds to DNA as a dimer. , 1990, Genes & development.

[7]  E. Reddy,et al.  Mutational analysis of Max: role of basic, helix-loop-helix/leucine zipper domains in DNA binding, dimerization and regulation of Myc-mediated transcriptional activation. , 1992, Oncogene.

[8]  Robert A. Weinberg,et al.  Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes , 1983, Nature.

[9]  G. Evan,et al.  Max and c-Myc/Max DNA-binding activities in cell extracts. , 1992, Oncogene.

[10]  M. Cole,et al.  Casein kinase II inhibits the DNA-binding activity of Max homodimers but not Myc/Max heterodimers. , 1992, Genes & development.

[11]  G. Evan,et al.  The role of c-myc in cell growth. , 1993, Current opinion in genetics & development.

[12]  M. Cole.  The myc oncogene: its role in transformation and differentiation. , 1986, Annual review of genetics.

[13]  V. Rotter,et al.  c-Myc trans-activates the p53 promoter through a required downstream CACGTG motif. , 1993, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[14]  R. Stein,et al.  Transforming growth factor beta 1 suppression of c-myc gene transcription: role in inhibition of keratinocyte proliferation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[15]  C. Dang,et al.  Binding and suppression of the Myc transcriptional activation domain by p107. , 1994, Science.

[16]  S Gaubatz,et al.  An E-box element localized in the first intron mediates regulation of the prothymosin alpha gene by c-myc , 1994, Molecular and cellular biology.

[17]  R. Eisenman,et al.  Myc and Max proteins possess distinct transcriptional activities , 1992, Nature.

[18]  Weinberg Ra.  The retinoblastoma gene and gene product. , 1992 .

[19]  R. Ralston.  Complementation of transforming domains in E1a/myc chimaeras , 1991, Nature.

[20]  J. Cleveland,et al.  Ornithine decarboxylase is a mediator of c-Myc-induced apoptosis , 1994, Molecular and cellular biology.

[21]  C. Dang,et al.  B-myc inhibits neoplastic transformation and transcriptional activation by c-myc , 1993, Molecular and cellular biology.

[22]  R. Eisenman,et al.  Myc and Max function as a nucleoprotein complex , 1992, Current Biology.

[23]  A. Patel,et al.  myc function and regulation. , 1992, Annual review of biochemistry.

[24]  R. Eisenman,et al.  Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. , 1991, Science.

[25]  H. Ruley.  Adenovirus early region 1A enables viral and cellular transforming genes to transform primary cells in culture , 1983, Nature.

[26]  G. Evan,et al.  Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max , 1992, Nature.

[27]  L. J. Veer,et al.  TATA-binding protein and the retinoblastoma gene product bind to overlapping epitopes on c-Myc and adenovirus E1A protein. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[28]  J. Nevins,et al.  E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. , 1992, Science.

[29]  N. Hay,et al.  Sequence-specific transcriptional activation by Myc and repression by Max , 1993, Molecular and cellular biology.

[30]  S. Maheswaran,et al.  Intracellular association of the protein product of the c-myc oncogene with the TATA-binding protein , 1994, Molecular and cellular biology.

[31]  K. A. Lee,et al.  A small-scale procedure for preparation of nuclear extracts that support efficient transcription and pre-mRNA splicing. , 1988, Gene analysis techniques.

[32]  P. Sharp,et al.  TFEB has DNA-binding and oligomerization properties of a unique helix-loop-helix/leucine-zipper family. , 1991, Genes & development.

[33]  H. Varmus,et al.  Definition of regions in human c-myc that are involved in transformation and nuclear localization , 1987, Molecular and cellular biology.

[34]  R. Weinberg.  The retinoblastoma gene and gene product. , 1992, Cancer surveys.

[35]  P. Chambon,et al.  The yeast UASG is a transcriptional enhancer in human hela cells in the presence of the GAL4 trans-activator , 1988, Cell.

[36]  S. Lowe,et al.  Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. , 1993, Genes & development.

[37]  R. Eisenman,et al.  New light on Myc and Myb. Part II. Myb. , 1990, Genes & development.

[38]  P. Leder,et al.  Evolutionarily conserved regions of the human c-myc protein can be uncoupled from transforming activity. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[39]  J. Nevins,et al.  A role for the adenovirus inducible E2F transcription factor in a proliferation dependent signal transduction pathway. , 1990, The EMBO journal.

[40]  R. Roeder,et al.  Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. , 1983, Nucleic acids research.

[41]  M. Cole,et al.  Immortalization by c-myc, H-ras, and Ela oncogenes induces differential cellular gene expression and growth factor responses , 1987, Molecular and cellular biology.

[42]  W. Gu,et al.  Opposite regulation of gene transcription and cell proliferation by c-Myc and Max. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[43]  E. White,et al.  Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. , 1993, Genes & development.

[44]  R. Eisenman,et al.  New light on Myc and Myb. Part I. Myc. , 1990, Genes & development.

[45]  J. Barrett,et al.  An amino-terminal c-myc domain required for neoplastic transformation activates transcription , 1990, Molecular and cellular biology.

[46]  R. DePinho,et al.  Myc family oncoproteins function through a common pathway to transform normal cells in culture: cross-interference by Max and trans-acting dominant mutants. , 1992, Genes & development.

[47]  E. Taparowsky,et al.  The transcription activation domains of v-Myc and VP16 interact with common factors required for cellular transformation and proliferation. , 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[48]  K. Struhl,et al.  Yeast GCN4 as a probe for oncogenesis by AP-1 transcription factors: transcriptional activation through AP-1 sites is not sufficient for cellular transformation. , 1992, Genes & development.

[49]  H. Ruley,et al.  Role of c-myc in the transformation of REF52 cells by viral and cellular oncogenes. , 1987, Oncogene.

[50]  M Lipp,et al.  Nuclear factor E2F mediates basic transcription and trans-activation by E1a of the human MYC promoter. , 1989, Genes & development.

[51]  G. Prendergast,et al.  Association of Myn, the murine homolog of Max, with c-Myc stimulates methylation-sensitive DNA binding and ras cotransformation , 1991, Cell.

[52]  J L Cleveland,et al.  The ornithine decarboxylase gene is a transcriptional target of c-Myc. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[53]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[54]  Jun Ma,et al.  GAL4-VP16 is an unusually potent transcriptional activator , 1988, Nature.

[55]  M. Cole,et al.  max encodes a sequence-specific DNA-binding protein and is not regulated by serum growth factors. , 1992, Oncogene.

[56]  M Lipp,et al.  E1A-dependent trans-activation of the human MYC promoter is mediated by the E2F factor. , 1989, Proceedings of the National Academy of Sciences of the United States of America.